Wittenberg Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-210,239
Closed -$3.11M 85
2024
Q1
$3.11M Hold
210,239
1.06% 20
2023
Q4
$2.82M Buy
210,239
+500
+0.2% +$6.32K 0.98% 24
2023
Q3
$2.59M Buy
209,739
+4,745
+2% +$57.5K 0.95% 23
2023
Q2
$2.52M Buy
204,994
+7,000
+4% +$87.5K 0.91% 27
2023
Q1
$2.43M Buy
197,994
+6,800
+4% +$79.9K 0.91% 26
2022
Q4
$2.19M Buy
191,194
+2,500
+1% +$20.6K 0.89% 26
2022
Q3
$708K Hold
188,694
0.3% 50
2022
Q2
$1.12M Hold
188,694
0.47% 43
2022
Q1
$1.19M Hold
188,694
0.45% 35
2021
Q4
$738K Hold
188,694
0.27% 46
2021
Q3
$911K Sell
188,694
-600
-0.3% -$3.13K 0.35% 37
2021
Q2
$1.21M Buy
189,294
+3,096
+2% +$20.4K 0.49% 31
2021
Q1
$1.17M Hold
186,198
0.54% 30
2020
Q4
$1.28M Hold
186,198
0.63% 28
2020
Q3
$620K Hold
186,198
0.33% 35
2020
Q2
$620K Hold
186,198
0.35% 38
2020
Q1
$400K Hold
186,198
0.22% 45
2019
Q4
$587K Buy
186,198
+1,080
+0.6% +$4.33K 0.23% 50
2019
Q3
$831K Sell
185,118
-58,570
-24% -$293K 0.36% 43
2019
Q2
$1.16M Sell
243,688
-30,998
-11% -$147K 0.5% 38
2019
Q1
$1.5M Sell
274,686
-8,070
-3% -$37.1K 0.64% 36
2018
Q4
$859K Sell
282,756
-41,034
-13% -$142K 0.4% 40
2018
Q3
$1.36M Buy
323,790
+1,271
+0.4% +$5.36K 0.56% 36
2018
Q2
$1.25M Buy
322,519
+165,791
+106% +$1.1M 0.53% 36
2018
Q1
$993K Buy
156,728
+50,204
+47% +$415K 0.43% 39
2017
Q4
$859K Buy
106,524
+23,886
+29% +$223K 0.37% 39
2017
Q3
$945K Buy
+82,638
New +$869K 0.41% 39

Other funds holding MACK

Wittenberg Investment Management's MACK Position: Q2 2024 in Review

Wittenberg Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 210,239 shares — an estimated $3.11M sold.

Wittenberg Investment Management first reported a position in MACK in Q3 2017 and held it in 27 quarters. The position peaked at $3.11M in Q1 2024. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Wittenberg Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Wittenberg Investment Management sold 210,239 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $3.11M.
  • Wittenberg Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2017 and held it in 27 quarters.
  • Wittenberg Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $3.11M in Q1 2024.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Wittenberg Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.